SCHEMBL12876144

SCHEMBL12876144

Cc1cccc(-c2nc(COC3CCCCO3)c(C=O)s2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.38
NPC1 O15118 4/20 0.38
PKM P14618 1/20 0.38
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
FFAR1 O14842 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
HRH3 Q9Y5N1 1/20 0.34
ALDH1A1 P00352 2/20 0.34
CASP3 P42574 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
HPGD P15428 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ICAM1 P05362 1/20 0.33
SELE P16581 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1199541 0.87 PPARG (0.40) PPARGPPARAKDM4CALDH1A1SMN1; SMN2
SCHEMBL12876150 0.84 FFAR1 (0.36) RAB9ANPC1PKMPPARGPPARA
SCHEMBL12876153 0.84 FFAR1 (0.38) RAB9ANPC1PKMPPARGPPARA
SCHEMBL12876163 0.83 KDM4C (0.35) RAB9ANPC1PKMPPARGPPARA
SCHEMBL4811119 0.80 KDM4E (0.35) NPC1PPARGPPARAFFAR1KDM4C
SCHEMBL12876224 0.78 PPARG (0.32) RAB9ANPC1PPARGPPARAKDM4C
SCHEMBL12876137 0.73 ATP4A (0.39) RAB9ANPC1PKMKDM4CALDH1A1
SCHEMBL1199248 0.73 GRIN1 (0.38) RAB9APPARGPPARAKDM4CALDH1A1
SCHEMBL12876196 0.73 KDM4C (0.33) RAB9ANPC1PPARGPPARAKDM4C
SCHEMBL8836774 0.73 NPC1 (0.35) RAB9ANPC1KDM4CICAM1SELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A RAB9A 2507/4885NPC1 3877/4885PKM 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.